Investigating the effect of nanocurcumin on patients with Alzheimer’s disease

Investigating the effect of nanocurcumin on brain volumetery and cognitive function of patients with Alzheimer’s disease-Interventional - Randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231016059737N3

Enrollment

Registered

2026-04-27

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s disease. Alzheimers disease, unspecified

Interventions

Intervention 1: Intervention group: patients with Alzheimer’s disease who will receive nanocurcumin soft gel (exirnanosina pharmaceutical company)at a dose of 40 mg per day for six months. Interventi

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with mild or moderate Alzheimer’s disease based on DSM-5 and NIA-AA 50-85 years old patients Ability to do cognitive tests and MRI

Exclusion criteria

Exclusion criteria: Patients with other neurological diseases such as Parkinson’s disease, stroke Use of anti-inflammatory or antioxidant medications Any contraindications for MRI

Design outcomes

Primary

Measure	Time frame
Brain volume. Timepoint: Beginning of the study and after 6 months of intervention. Method of measurement: 1.5Tesla structural MRI.;Cognitive function. Timepoint: At the beginning of study and after 6 months of intervention. Method of measurement: Montreal Cognitive Assessment (MoCA) test.	—

Secondary

Measure	Time frame
Gender. Timepoint: At the beginning of study. Method of measurement: Inquiring about gender.;Demographic factor(age). Timepoint: At the beginning of study. Method of measurement: Based on date of birth.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahidreza ostovan

Shiraz University of Medical Sciences

ostovanv@gmail.com+98 71 3612 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026